Faculty Bio - Joseph P. Costantino, DrPH
Director, NSABP Biostatistical Center
Professor, Biostatistics )
BS, Bethany College, 1972
MPH, University of Pittsburgh, 1974
DrPH, University of Pittsburgh, 1976
Primary research interest is the design, implementation and analysis of clinical trials. Collaboration in clinical trials of the National Surgical Breast and Bowel Project (NSABP) has been a major focus dealing with trials involving the evaluation of therapies for the prevention or treatment of breast cancer and the prevention and treatment of colorectal cancer. The development of statistical methodologies for race-specific cancer risk assessment and the risk-benefit assessment of therapies associated with multiple endpoints of potential benefit and harm has evolved from this collaboration. A previous area of research focus involved the assessment of health effects from occupational and environmental exposures to airborne pollutants. This work dealt with the study and long-term follow-up of large occupational cohorts who were exposed to work-related air-borne pollution. The thrust of this effort was to quantify health risks from pollution exposure and to evaluate methodologies to lower exposure and reduce the risks of diseases associated with exposure.
BIOST 2045: Analysis of Case-Control Studies
“Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP Study of Tamoxifen and Raloxifene.” Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N. Cancer Prev Res 5:1321-29, 2012.
"Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials." Cecchini S, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, Weissfeld JL, Wolmark N. Cancer Prev Res 5 (4): 583-592, 2012.
"Bevacizumab added to neoadjuvant chemotheraphy for breast cancer (B-40)." Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. NEJM 366:1637-1640, 2012.
"Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women." Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. J Natl Cancer Inst (in press, published on-line ahead of press, May 11, 2011).
"Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years and Older." Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W. J Clin Oncol (in press, published on-line ahead of press, May 2, 2011).
"The impact of systemic therapy following ductal carcinoma in situ." Eng-Wong J, Costantino JP, Swain SM. J Natl Cancer Inst Monogr 41:200-203, 2010.
"Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project breast cancer chemoprevention trials." Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N. J Natl Cancer Inst Monogr 41:181-186, 2010.
"Statistical design and analysis of phase III clinical trials." Costantino JP, Anderson S, Yothers G. In: Kuerer’s Breast Surgical Oncology. Ch 37. Kuerer HM Ed, McGraw-Hill, New York, NY, p. 441-450, 2010.
"Akt phosphorylation at Ser473 predicts benefit to paclitaxel chemotherapy in node-positive breast cancer." Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong J-H, Wolmark N, Kidwell K, Paik S, Swain SM. J Clin Oncol 28:2974-81, 2010.
"Update of the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial in preventing breast cancer." Vogel VG, Costantino JP, Wickerham L, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL III, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Cancer Prev Res 3(6):696-706, 2010.
"Longer therapy, iatrogenic amenorrha, and survival in breast cancer." Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK,Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. NEJM 362:2053-65, 2010.
"Use of 5-alpha reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 clinical guideline." Kramer BS, Hagerty KL, Justman S, Somerfield M, Albertson PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. J Clin Oncol 27:1502-16, 2009.
"Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of the NSABP B-30 trial." Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Wolmark N, Ganz PA. Breast Cancer Res Treat 113:315-20, 2009.
"Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen-negative breast cancer." Shen Y, Costantino JP, Qin, J. J Natl Cancer Inst 100:1448-53, 2008.
"Nonparametric inference on median residual life function." Jeong J, Jung S, Costantino JP. Biometrics 64:157-63, 2008.
"Inference of tamoxifen’s effects on prevention of breast cancer from a randomized controlled trial." Shen Y, Qin J, Costantino JP. J Am Stat Assoc 102 (48):1235-1243, 2007.
"Compliance with patient-reported outcomes: Methodological and practical approaches." Land SR, Ritter MW, Costantino JP, Julian TB, Cronin WM, Haile SR, Wolmark N, Ganz PA. J Clin Oncol 25(16):2205-11, 2007.
"Projecting individual absolute invasive breast cancer risk in African American Women." Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L. J Natl Cancer Inst 99:1782-92, 2007.
"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial." Vogel V, Costantino JP, Wickerham DL, Cronin W, Cecchini R, Wolmark N. JAMA 295:2727-41, 2006.
"Re: Tamoxifen for the prevention of Breast Cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study." Fisher B, Costantino JP. J Natl Cancer Inst 98:643-44, 2006.
"Application of smoothing methods to evaluate treatment-prognostic factors interactions in breast cancer data." Jeong J, Costantino JP. Cancer Investigation 24:288-293, 2006.
"The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 breast cancer prevention study." Land S, Wickerham DL, Costantino JP, Ritter M, Vogel V, Lee M, Pajon ER, Wade JL, Dakhil S, Lockhart JB, Wolmark N, Ganz PA. JAMA 295(23)2742-51, 2006.
"Endogenous sex hormones, risk of breast cancer and response to tamoxifen: an ancillary study in the NSABP Breast Cancer Prevention Trial." Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Wolmark N, Dowsett M, Folkerd EJ, Willett WC, Vogel VG, Hankinson SE. J Natl Cancer Inst 98:110-115, 2006.
"Is tamoxifen a risk for retinal vascular-occlusive disease?" Gorin MB, Costantino JP, Kulacoglu DN, Demirci YK, Wickerham DL, Fisher B, Wolmark N. Retina 25(4):523-526, 2005.
"Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial." Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. J. Obstet. Gynecol 192:1230-9, 2005.
"The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials." Martino S, Costantino J, McNabb M, Mershon J, Bryant J, Powles T, Secrest RJ. Oncologist 9:116-125, 2004.
"Lower-category benign breast disease and the risk of invasive breast cancer." Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. J Natl Cancer Inst 96 (7): 616-620, 2004.
"Breast cancer prevention: The U.S.A. viewpoint." Wickerham DL, Costantino JP. In: Breast Cancer Management: Application of Evidence to Patient Care, 2nd Ed. Lippincott Williams & Wilkins, Philadelphia, PA, p. 535-547, 2003.
"Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The breast cancer prevention trial." Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN. Brit. J. Haematol 120: 109-116, 2003.
"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 from the NSABP-P1 Breast Cancer Prevention Trial." King M-C, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Costantino J, Wickerham L, Wolmark N, Fisher B. JAMA 2001; 286:2251-2256.
"Tamoxifen and depression: More Evidence form the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study." Day R, Ganz P, Costantino JP. J Natl Cancer Inst 2001; 93:1615-1623.
"Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view." Costantino JP, Vogel VG. Clinical Breast Cancer 2001; 2:41-46.
"Reducing the risk of breast cancer: Balancing the risk-benefit analogies." Costantino JP, Vogel VG, Wickerham DL. Prevention Care and Cancer 2001; 21(9):13-21.
"Risk/benefit assessment: Clinical trial versus clinical practice settings." Proceedings of the NIH Symposium on Selective Estrogen Receptor Modulators. Costantino JP. Annals NY Acad Sci 2001; 949:280-286.
"Benefit-risk assessment." In: Biostatistics in Clinical Trials. Costantino JP, p. 18-25, 2001.
"Validating and improving models for projecting the absolute risk of breast cancer." Gail M, Costantino JP. J Natl Cancer Inst 2001;93:334-335.
"Tamoxifen and novel cardiac risk factors in healthy women: evidence for an anti-inflamatory effect." Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, et al. Arterioscler, Thromb and Vasc Biol 2001; 21(2):255-261.
"Lack of cardiovascular disease risk reduction from tamoxifen therapy: results from the Breast Cancer Prevention Trial." Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, et al. J Natl Cancer Inst 2001;93:16-21.
"The impact of split-night polysomnography for diagnosis and positive pressure therapy titration on treatment acceptance and adherence in sleep apnea/hypopnea." Sanders MH, Costantino JP, Strollo PJ, Strunicki K, Atwood CW. Sleep 23:17-24, 2000.
"Evaluating women for breast cancer risk reduction therapy." Costantino JP. In: ASCO Fall Education Book. American Society of Clinical Oncology, p. 208-214,1999.
Issues and findings in the evaluation of occuaptional risk among women high nickel alloys workers cohort." Arena VC, Costantino JP, Sussman NB, and Redmond CK. Am J Ind Med, 36(4)114-121. 1999.
"Weighing the risks and benefits of tamoxifen for preventing breast cancer." Gail MH, Costantino JP, et. al. J Natl Cancer Inst 91:1829-46, 1999.
"Validation studies for models to project the risk of invasive and total breast cancer incidence." Costantino JP, Gail MH, et al. J Natl Cancer Inst 91:1541-48,1999.
"Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant breast and bowel project P-1 study." Day R, Ganz PA, Costantino JP, et al. J Clin Oncol 17:2659-2669,1999.
"Alternative comparison populations to assess occupation-related mortality risk: Results for the high nickel alloys workers cohort." Arena VC, Sussman NB, Costantino JP, Redmond CK Trauth JM. J Occup Environ Med, 40(10)907-916, 1998.
"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study." Fisher B, Costantino JP, Wicherham DL, Redmond CK, Kavanah M et al. J Natl Cancer Inst 90:1371-88, 1998.
"Long-term tamoxifen use and potential ocular toxicity." Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, et al. Am J Ophthal 125:493-501, 1998.
"Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial." Ganz PA, Day R, Costantino J. Stat Med 17:613-622,1998.
"Statistical concepts and biomedical research." Redmond CK, Costantino JP, Anderson S, Yu K. Urol Oncology 2:166-170, 1997.
"Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Five year observations concerning lobular carcinoma in situ (LCIS)." Fisher ER, Costantino JP, Fisher B, et. al. Cancer 78(7):1403-16, 1996.
"Occupational related cancer risk among coke oven workers: Results of 30 years of follow-up." Costantino JP, Redmond CK, Bearden A. J Occ Environ Med 37(5):1-8, 1995.
"Pathologic findings from the National Surgical Adjuvant Breast Project B-17: Intraductal Carcinoma." Fisher ER, Costantino JP, Palekar AS et. al. Cancer 75:1310-1319, 1995.
"Accuracy of end-tidal and transcutaneous PaCO2 monitoring during sleep." Sanders MH, Kern NB, Costantino JP et. al. Chest 106:472-83, 1994.
"Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer." Fisher B, Costantino JP, et. al. New Engl J Med 328(22):1581-1586, 1993.
"Recent developments in the multistage modeling of cohort data for carcinogenic risk assessment." Mazumdar S, Redmond CK, Costantino JP et. al. Environ Hlt Perspect 90:271-277, 1991.
"Polysomnography early after uvulopalatopharyngoplasty as a predictor of late postoperative results." Sanders MH, Costantino JP, Johnston JT. Chest 97(4):913-919, 1990.
316 Parran Hall
130 DeSoto Street
Pittsburgh, PA 15261
Last reviewed: May 8, 2013